Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4–6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR ant...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Dis
Asıl Yazarlar: Liu, Qiuli, Tong, Dali, Liu, Gaolei, Xu, Jing, Do, Khang, Geary, Kyla, Zhang, Dianzheng, Zhang, Jun, Zhang, Yao, Li, Yaoming, Bi, Gang, Lan, Weihua, Jiang, Jun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5596596/
https://ncbi.nlm.nih.gov/pubmed/28837141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2017.417
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller